Lyra Therapeutics, Inc.

NasdaqGM:LYRA Stock Report

Market Cap: US$12.5m

Lyra Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Maria Palasis

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage32.7%
CEO tenure9.9yrs
CEO ownershipn/a
Management average tenure2.4yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

CEO Compensation Analysis

How has Maria Palasis's remuneration changed compared to Lyra Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

Compensation vs Market: Maria's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Maria's compensation has increased whilst the company is unprofitable.

CEO

Maria Palasis (59 yo)

9.9yrs

Tenure

US$1,785,375

Compensation

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

Leadership Team

NamePositionTenureCompensationOwnership
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 49.9k
Maria Palasis
CEO, President & Director9.9yrsUS$1.79mno data
Carmichael Roberts
Co-Founderno datano datano data
Jason Cavalier
CFO, Treasurer & Secretary3.3yrsUS$1.07mno data
Ray Knox
Vice President of Operationsno datano datano data
Ronan O'Brien
Chief Legal Officer1.2yrsno datano data
Vineeta Belanger
Senior Vice President of Clinical Affairsno datano datano data
Robert Richard
Senior Vice President of Technical Operations1.8yrsUS$666.79kno data
Robert Kern
Chief Clinical Advisor3.8yrsno datano data
Gloria Cosgrove
Senior Vice President of Quality1.9yrsno datano data
Allison Nance
Senior Vice President of Regulatory Affairs1.9yrsno datano data
Elazer Edelman
VP of Finance & Riskno datano datano data

2.4yrs

Average Tenure

59yo

Average Age

Experienced Management: LYRA's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 49.9k
Maria Palasis
CEO, President & Director9.9yrsUS$1.79mno data
James Tobin
Lead Independent Director2.8yrsUS$152.31k0%
$ 0
W. Smith
Independent Director5.1yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4.2yrsUS$333.93kno data
C. Merrifield
Independent Director5.3yrsUS$113.06k0.017%
$ 2.2k
Robert S. Langer
Member of Scientific Advisory Board4.2yrsUS$19.36kno data
Michael Dake
Member of Medical Advisory Boardno datano datano data
William Gray
Member of Medical Advisory Boardno datano datano data
Mahmood Razavi
Member of Medical Advisory Boardno datano datano data
Gary Ansel
Member of Medical Advisory Boardno datano datano data
I. Baumgartner
Member of Medical Advisory Boardno datano datano data

4.2yrs

Average Tenure

73yo

Average Age

Experienced Board: LYRA's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 17:17
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lyra Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Justin ZelinBTIG
null nullBTIG